Please login to the form below

Not currently logged in
Email:
Password:

CML

This page shows the latest CML news and features for those working in and with pharma, biotech and healthcare.

Inside the patient-centricity bubble

Inside the patient-centricity bubble

There has been some egregious behaviour in the industry in terms of drug pricing, ”he said referring to the net price of CML drugs, which have tripled over the course of

Latest news

More from news
Approximately 4 fully matching, plus 58 partially matching documents found.

Latest Intelligence

  • Deal Watch January 2017 Deal Watch January 2017

    With an enterprise value of $5.2bn this acquisition brings access to Iclusig (ponatinib), approved for chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL), as well as brigatinib in phase

  • Deal Watch May 2016 Deal Watch May 2016

    In addition Incyte was granted an exclusive licence to Inclusig [the only approved BCR-ABL inhibitor with activity against the T315I mutation approved in Europe for chronic myeloid leukaemia (CML) and

  • Seismic shifts: Hepatitis C and payers Seismic shifts: Hepatitis C and payers

    Analogues such as Glivec (imatanib) which transformed outcomes in CML need to be utilised to demonstrate that tough investment decisions by payers do pay off.

  • Deal Watch table for December 2014 Deal Watch table for December 2014

    Iclusig (ponatinib), inhibitor of BCR-ABL, for resistant and intolerant CML and Ph ALL (JP NDA). ... JP 9 other Asian countries (CML, chronic myeloid leukaemia ; Ph ALL, Philadelphia-chromosome positive acute lymphoblastic leukaemia).

  • Interview: Harvey Berger and Timothy Clackson, Ariad Interview: Harvey Berger and Timothy Clackson, Ariad

    cancer: chronic myeloid leukaemia (CML) and Philadelphia chromosome positive acute lymphoblastic leukaemia (Ph+ ALL). ... treatment. “ CML drugs represent real breakthroughs in treatments of patients who would otherwise be very difficult to treat,”

More from intelligence
Approximately 0 fully matching, plus 6 partially matching documents found.

Latest appointments

  • Helen Parfitt joins Research Partnership Helen Parfitt joins Research Partnership

    She will also focus on the firm’s recently expanded oncology portfolio, which has added squamous cell carcinoma of the head and neck (SCCHN) and chronic myeloid leukaemia (CML) to its

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
IGNIFI

We’re IGNIFI. An independent creative agency, we help spark and sustain successful brands for some of the biggest names in...

Latest intelligence

PM Society Digital Awards – the power of together
Our chief executive, Emma Statham, writes about the value of awards and the power of together....
Seduction_feature_image_thumb.jpg
Seduce anyone in four simple steps
You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....

Infographics